Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

Early-stage research gains another funding boost

March 23, 2012
Research and Development, Sales and Marketing GSK, Index Ventures, Janssen, R&D

GlaxoSmithKline and Janssen are among the key investors in a venture capital fund aimed solely at identifying promising pharma start-ups.  …

News

NICE recommends Incivo for hepatitis C

March 16, 2012
Sales and Marketing Incivo, Janssen, NICE, Victrelis, telaprevir

NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the …

News
Zytiga image

Charity attacks Scottish decision on Zytiga

March 14, 2012
Sales and Marketing Janssen, NICE, PAS, Prostate Cancer Charity, Zytiga

Scotland’s medicines regulator has turned down Janssen’s prostate cancer pill Zytiga, leading to a backlash from charities. The Scottish Medicines …

News
Zytiga image

Strong Zytiga study results could increase uptake

March 12, 2012
Research and Development, Sales and Marketing IDMC, Janssen, Provenge, Zytiga, prostate

Janssen’s prostate cancer pill Zytiga could be on course to target a larger number of patients following a positive late-stage …

News
Victrelis picture

NICE recommends Victrelis in speedy review

March 9, 2012
Sales and Marketing Incivo, Janssen, Merck, NICE, Pegasus, Victrelis

NICE is recommending Merck’s hepatitis C pill Victrelis for funding in the NHS, in an expedited review.  In its final …

News
Zytiga image

Cancer Drugs Fund should not be used across the UK

March 7, 2012
Sales and Marketing CDF, Janssen, NICE, Zytiga, myloma, prostate

The Prostate Cancer Charity has said that extending England’s Cancer Drugs Fund to the UK will not solve the issue …

News

Janssen launches hep C support programme

February 27, 2012
Medical Communications, Sales and Marketing BUPA, Copegas, Incivo, Janssen, Pegasys, hep C

Janssen has launched a hepatitis C support programme for patients in the UK to help with medicine adherence and healthy …

News

Alex Gorsky named new chief executive of J&J

February 22, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon

Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …

Appointment
Zytiga image

Zytiga approved in Wales – for now

February 21, 2012
Sales and Marketing AWMSG, CDF, Janssen, NICE, Wales, Zytiga

Janssen’s cancer treatment Zytiga has been approved in Wales, in contrast to its rejection by NICE. The All Wales Medicines …

News

Janssen signs deal with rising star Forma

January 11, 2012
Research and Development Forma, Janssen, alliance

Janssen has signed a deal with Forma Therapeutics to discover, and develop drugs that target tumour metabolism mechanisms.Forma focuses on …

News
Risperdal image

J&J to pay $1 billion for Risperdal charges

January 9, 2012
Sales and Marketing J&J, JJ, Janssen, Risperdal

Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …

News

Janssen inks $150m deal for blood cancer drug

December 12, 2011
Research and Development, Sales and Marketing Janssen, Pharmacyclics

Janssen biotech has signed a licensing deal with Pharmacyclics for its investigational blood cancer drug. The firm has paid $150 …

News

Janssen sets up new mental health social networking site

November 28, 2011
Medical Communications J&J, JJ, Janssen, NHS

Janssen and the NHS Confederation have established a new mental health social networking site. The service, which will be free …

News
Social moon image

Alex Butler leaves Janssen to set up Social Moon pharma network

October 27, 2011
Medical Communications Alex Bytler, Jansse, Janssen, comms

Social media guru Alex Butler has left Janssen to establish Social Moon, a digital-only marketing and comms agency for the …

News
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011
Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025